4//SEC Filing
Noy Shlomo 4
Accession 0001178913-25-004147
CIK 0002022416other
Filed
Dec 30, 7:00 PM ET
Accepted
Dec 31, 1:07 PM ET
Size
18.2 KB
Accession
0001178913-25-004147
Insider Transaction Report
Form 4
Noy Shlomo
Director
Transactions
- Award
Ordinary Shares
2025-02-09+1,587→ 1,587 total(indirect: By Guangzhou Sino-Israel Biotech Fund) - Award
Stock Option (right to buy ordinary shares)
2025-02-09+1,872→ 1,872 total(indirect: By Guangzhou Sino-Israel Biotech Fund)Exercise: $18.90From: 2026-02-09Exp: 2035-02-09→ Ordinary Shares (1,872 underlying)
Holdings
- 14,721(indirect: By Guangzhou Sino-Israel Biotech Fund)
Ordinary Shares
Footnotes (8)
- [F1]Represents ordinary shares underlying RSUs granted to Guangzhou Sino-Israel Biotech Fund ("GIBF") by the Issuer for director services provided by the Reporting Person and Avner Lushi. The shares subject to this award vest in full on the first anniversary of the grant date, subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the shares) continued service through such date.
- [F2]The number of ordinary shares reported in this row has been adjusted retroactively to reflect a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
- [F3]The Reporting Person possesses shared voting and investment authority with respect to the securities reported in this line by virtue of his serving as Chief Medical Officer of GIBF. The equity interests of GIBF are held by various individuals and entities. The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.
- [F4]There were no transactions effected in respect of the ordinary shares reported in this row, and the holdings in this row are being included for informational purposes only.
- [F5]The number of ordinary shares reported in this row has been adjusted downwards to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
- [F6]Represents stock options granted by the Issuer to GIBF for director services provided by the Reporting Person and Avner Lushi (each, with respect to half of the options).
- [F7]The number of options to purchase ordinary shares, and underlying ordinary shares, reported in this row have been adjusted downwards, and the exercise price of those options has been adjusted proportionately upwards, to reflect the 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
- [F8]All of the stock options reported in this row vest (and become exercisable) on the first anniversary of the date of grant (i.e., on February 9, 2026), subject to the Reporting Person's or Mr. Lushi's (each, with respect to half of the options) continued service through such date.
Documents
Issuer
Silexion Therapeutics Corp
CIK 0002022416
Entity typeother
Related Parties
1- filerCIK 0002033211
Filing Metadata
- Form type
- 4
- Filed
- Dec 30, 7:00 PM ET
- Accepted
- Dec 31, 1:07 PM ET
- Size
- 18.2 KB